Comparative Pharmacology
Head-to-head clinical analysis: UNIPEN versus VEETIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UNIPEN versus VEETIDS.
UNIPEN vs VEETIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unipen (nafcillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), blocking transpeptidation and autolysin inhibition.
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
500 mg to 2 g orally or intravenously every 4 to 6 hours; maximum 12 g/day IV for serious infections.
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 7-10 hours in anuria or severe renal impairment.
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment.
Renal: 70-90% unchanged via tubular secretion and glomerular filtration; biliary: minor (<10%); fecal: minimal.
Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic